Dana-Farber Cancer Institute | Strategic Alliance Partners

August 30, 2024

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

August 30, 2024

Sara M. Tolaney, MD, MPH, discusses the sequential use of antibody-drug conjugates in the treatment of patients with breast cancer.

August 29, 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

August 29, 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

August 29, 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

August 29, 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

August 29, 2024

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

August 28, 2024

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

August 27, 2024

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

August 26, 2024

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

August 26, 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

August 26, 2024

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

August 23, 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

August 23, 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

August 22, 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

August 22, 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

August 22, 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

August 22, 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.